Sanofi Wins EU Approval for Sarclisa SC in Multiple Myeloma
PARIS, France, June 8, 2026 Sanofi announced that the European Commission has approved Sarclisa® (isatuximab) subcutaneous (SC) for the...
Multiple Myeloma
Advertisement
AbbVie Expands Oncology Pipeline With New ASCO Data
North Chicago, Ill., USA – May 21, 2026 AbbVie announced new oncology research findings ahead of the 2026 American...
Regeneron’s Lynozyfic Shows 100% Complete Responses in AL Amyloidosis Trial
TARRYTOWN, N.Y., May 21, 2026 Regeneron Pharmaceuticals announced highly encouraging early clinical data from the Phase 1/2 LINKER-AL2 trial...
Mabwell Expands MAIWEIJIAN Approval for Cancer Bone Complications in China
SHANGHAI, China, May 20, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has approved the supplemental application...
Pfizer ELREXFIO Phase 3 Trial Improves Survival Outcomes
New York, United States | April 29, 2026 Pfizer Inc. has reported positive Phase 3 clinical trial results for...
Advertisements
Eli Lilly to Acquire Kelonia for In Vivo CAR-T Breakthrough
INDIANAPOLIS and BOSTON, Mass., April 20, 2026 Eli Lilly and Company has announced a landmark agreement to acquire Kelonia...
Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
Gilead to Acquire Arcellx in $7.8B Cell Therapy Deal
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
FDA Approves DARZALEX FASPRO Quadruplet for NDMM Care
HORSHAM, PENNSYLVANIA | January 27, 2026 — Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA)...
Vyriad Secures $25M to Advance In Vivo CAR-T VV169
Rochester, Minnesota | December 23, 2025 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies, announced the...
Advertisement
